Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Harmonization of Next-Generation Sequencing Procedure in Italian Laboratories: A Multi-Institutional Evaluation of the SiRe® Panel.

Malapelle U, Pepe F, Pisapia P, Sgariglia R, Nacchio M, De Luca C, Lacalamita R, Tommasi S, Pinto R, Palomba G, Palmieri G, Vacirca D, Barberis M, Bottillo I, Grammatico P, Grillo LR, Costa V, Smeraglio R, Bruzzese D, Troncone G.

Front Oncol. 2020 Mar 11;10:236. doi: 10.3389/fonc.2020.00236. eCollection 2020.

2.

miRNAs as Key Players in the Management of Cutaneous Melanoma.

Lorusso C, De Summa S, Pinto R, Danza K, Tommasi S.

Cells. 2020 Feb 11;9(2). pii: E415. doi: 10.3390/cells9020415. Review.

3.

KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy.

Pinto R, Petriella D, Lacalamita R, Montrone M, Catino A, Pizzutilo P, Botticella MA, Zito FA, Del Bene G, Zonno A, Tommasi S, De Summa S.

Cancers (Basel). 2019 Aug 9;11(8). pii: E1145. doi: 10.3390/cancers11081145.

4.

Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy.

Brunetti O, Badalamenti G, De Summa S, Calabrese A, Argentiero A, Fucci L, Longo V, Galetta D, Perrotti PMS, Pinto R, Petriella D, Danza K, Tommasi S, Leonetti F, Silvestris N.

Cancers (Basel). 2019 May 29;11(6). pii: E749. doi: 10.3390/cancers11060749.

5.

The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).

Guida M, Tommasi S, Strippoli S, Natalicchio MI, De Summa S, Pinto R, Cramarossa A, Albano A, Pisconti S, Aieta M, Ridolfi R, Azzariti A, Guida G, Lorusso V, Colucci G.

BMC Cancer. 2018 May 10;18(1):552. doi: 10.1186/s12885-018-4479-2.

6.

Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets.

Silvestris N, Brunetti O, Pinto R, Petriella D, Argentiero A, Fucci L, Tommasi S, Danza K, De Summa S.

Expert Opin Ther Targets. 2018 May;22(5):453-461. doi: 10.1080/14728222.2018.1456530. Epub 2018 Mar 27.

PMID:
29561217
7.

Hierarchical clustering analysis identifies metastatic colorectal cancers patients with more aggressive phenotype.

Opinto G, Silvestris N, Centonze M, Graziano G, Pinto R, Fucci L, Simone G, Mangia A.

Oncotarget. 2017 Sep 23;8(50):87782-87794. doi: 10.18632/oncotarget.21213. eCollection 2017 Oct 20.

8.

Six low-penetrance SNPs for the estimation of breast cancer heritability: A family-based study in Caucasian Italian patients.

De Summa S, Graziano F, Pilato B, Pinto R, Danza K, Lacalamita R, Serratì S, Sambiasi D, Grassi M, Tommasi S.

Oncol Lett. 2017 Oct;14(4):4384-4390. doi: 10.3892/ol.2017.6725. Epub 2017 Aug 4.

9.

TGFbeta and miRNA regulation in familial and sporadic breast cancer.

Danza K, De Summa S, Pinto R, Pilato B, Palumbo O, Carella M, Popescu O, Digennaro M, Lacalamita R, Tommasi S.

Oncotarget. 2017 Jan 30;8(31):50715-50723. doi: 10.18632/oncotarget.14899. eCollection 2017 Aug 1.

10.

GATK hard filtering: tunable parameters to improve variant calling for next generation sequencing targeted gene panel data.

De Summa S, Malerba G, Pinto R, Mori A, Mijatovic V, Tommasi S.

BMC Bioinformatics. 2017 Mar 23;18(Suppl 5):119. doi: 10.1186/s12859-017-1537-8.

11.

Next-generation sequencing: advances and applications in cancer diagnosis.

Serratì S, De Summa S, Pilato B, Petriella D, Lacalamita R, Tommasi S, Pinto R.

Onco Targets Ther. 2016 Dec 2;9:7355-7365. eCollection 2016. Review.

12.

Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a Caucasian family.

De Summa S, Guida M, Tommasi S, Strippoli S, Pellegrini C, Fargnoli MC, Pilato B, Natalicchio I, Guida G, Pinto R.

Oncotarget. 2017 May 2;8(18):29751-29759. doi: 10.18632/oncotarget.12777.

13.

β-catenin interaction with NHERF1 and RASSF1A methylation in metastatic colorectal cancer patients.

Schirosi L, Mazzotta A, Opinto G, Pinto R, Graziano G, Tommasi S, Fucci L, Simone G, Mangia A.

Oncotarget. 2016 Oct 18;7(42):67841-67850. doi: 10.18632/oncotarget.12280.

14.

miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype.

Tommasi S, Pinto R, Danza K, Pilato B, Palumbo O, Micale L, De Summa S.

Oncotarget. 2016 Dec 6;7(49):80363-80372. doi: 10.18632/oncotarget.10345.

15.

BRCA1-2 diagnostic workflow from next-generation sequencing technologies to variant identification and final report.

Pilato B, Pinto R, De Summa S, Petriella D, Lacalamita R, Danza K, Paradiso A, Tommasi S.

Genes Chromosomes Cancer. 2016 Oct;55(10):803-13. doi: 10.1002/gcc.22383. Epub 2016 Jul 4.

PMID:
27225819
16.

The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response.

Pinto R, De Summa S, Strippoli S, Pilato B, Azzariti A, Guida G, Guida M, Tommasi S.

Oncotarget. 2016 May 3;7(18):25135-49. doi: 10.18632/oncotarget.7175.

17.

MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitors.

Pinto R, Strippoli S, De Summa S, Albano A, Azzariti A, Guida G, Popescu O, Lorusso V, Guida M, Tommasi S.

Expert Opin Ther Targets. 2015;19(8):1027-35.

PMID:
26156293
18.

Proteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutation.

Garrisi VM, Strippoli S, De Summa S, Pinto R, Perrone A, Guida G, Azzariti A, Guida M, Tommasi S.

PLoS One. 2014 Dec 1;9(12):e112025. doi: 10.1371/journal.pone.0112025. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0122943. Stefania, Tommasi [corrected to Tommasi, Stefania].

19.

Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients.

Danza K, De Summa S, Pilato B, Carella M, Palumbo O, Popescu O, Paradiso A, Pinto R, Tommasi S.

J Transl Med. 2014 Nov 19;12:319. doi: 10.1186/s12967-014-0319-6.

20.

MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis.

Danza K, De Summa S, Pinto R, Pilato B, Palumbo O, Merla G, Simone G, Tommasi S.

Oncotarget. 2015 Jan 1;6(1):471-83.

Supplemental Content

Loading ...
Support Center